An independent data monitoring committee recommended that Argos Therapeutics Inc. (Nasdaq: ARGS) discontinue its Phase 3 ADAPT clinical trial of rocapuldencel-T for futility. The stock price plummeted $2.92 to close at $1.47.
Argos Therapeutics advised to halt study
February 22, 2017 at 16:56 PM EST